EUCTR2004-000614-39-IT
Active, not recruiting
Not Applicable
A multicenter, randomized, double blind study comparing the clinical effects of intravenous montelukast with palcebo in patients with acute asthma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- MERCK SHARP DOHME
- Enrollment
- 550
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 (ASTRID – Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril in type 2 Diabetics). - ASTRIDEUCTR2004-000703-18-ESSOLVAY PHARMACEUTICALS GMBH440
Active, not recruiting
Not Applicable
A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2. ASTRID Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril in type 2 Diabetics .essential hypertensionMedDRA version: 6.1Level: PTClassification code 10015488EUCTR2004-000703-18-ITSOLVAY PHARMA440
Active, not recruiting
Not Applicable
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney DiseaseEUCTR2006-003173-27-PLAmgen Ltd334
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Double-blind Study Comparing De Novo OnceMonthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction ofAnemia in Subjects With Chronic Kidney Disease Not Receiving DialysisAnemia in subjects with chronic kidney disease not receiving dialysisMedDRA version: 9.1Level: LLTClassification code 10002272Term: AnemiaMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseEUCTR2006-003173-27-PTAmgen Ltd540
Active, not recruiting
Phase 1
A Multicenter, Randomized, Double-blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving DialysisAnemia in subjects with chronic kidney disease not receiving dialysisMedDRA version: 9.1 Level: LLT Classification code 10002272 Term: AnemiaMedDRA version: 9.1 Level: LLT Classification code 10064848 Term: Chronic kidney diseaseEUCTR2006-003173-27-GBAmgen Ltd540